Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$93.2 million.

  • Summit Therapeutics' Free Cash Flow fell 20687.2% to -$93.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$270.2 million, marking a year-over-year decrease of 13905.01%. This contributed to the annual value of -$142.2 million for FY2024, which is 8500.29% down from last year.
  • Latest data reveals that Summit Therapeutics reported Free Cash Flow of -$93.2 million as of Q3 2025, which was down 20687.2% from -$66.7 million recorded in Q2 2025.
  • Summit Therapeutics' Free Cash Flow's 5-year high stood at $5.2 million during Q4 2022, with a 5-year trough of -$93.2 million in Q3 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$20.7 million (2021), whereas its average is -$29.2 million.
  • As far as peak fluctuations go, Summit Therapeutics' Free Cash Flow skyrocketed by 15593.07% in 2022, and later tumbled by 47417.8% in 2023.
  • Summit Therapeutics' Free Cash Flow (Quarter) stood at -$9.3 million in 2021, then surged by 155.93% to $5.2 million in 2022, then plummeted by 474.18% to -$19.5 million in 2023, then tumbled by 150.18% to -$48.7 million in 2024, then tumbled by 91.33% to -$93.2 million in 2025.
  • Its Free Cash Flow was -$93.2 million in Q3 2025, compared to -$66.7 million in Q2 2025 and -$61.6 million in Q1 2025.